Christopher Dvorak, MD
Pediatric Hematology-Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Dvorak’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A69570 · Cancelled
Licence status: Cancelled · since 1999 · Osmania University, Osmania Medical College.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$39,347 in 2025
| 2025 | 5 | 19 | $28,840 | $39,347 |
| 2024 | 3 | 3 | $2,840 | $2,840 |
| 2023 | 2 | 14 | $12,195 | $17,404 |
| 2022 | 4 | 7 | $17,286 | $17,353 |
| 2021 | 5 | 12 | $28,315 | $28,315 |
| 2020 | 4 | 5 | $6,200 | $6,324 |
| 2019 | 3 | 26 | $17,347 | $32,884 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alexion Pharmaceuticals | Ultomiris | $38,713 | 12 payments
|
| Mesoblast | Ryoncil | $250 | 2 payments
|
| Sobi | Gamifant | $175 | 3 payments
|
| Medexus Pharma | Grafapex | $123 | 1 payment
|
| Jazz Pharmaceuticals | Defitelio | $87 | 1 payment
|
See all 19 published payments
| Alexion Pharmaceuticals | Consulting · 2025-10-13 | None | $14,040 |
| Alexion Pharmaceuticals | Travel · 2025-10-13 | None | $33 |
| Alexion Pharmaceuticals | Travel · 2025-10-13 | None | $38 |
| Mesoblast | Meals · 2025-09-15 | Ryoncil | $137 |
| Alexion Pharmaceuticals | Meals · 2025-09-03 | None | $48 |
| Alexion Pharmaceuticals | Meals · 2025-09-03 | None | $16 |
| Alexion Pharmaceuticals | Travel · 2025-09-02 | None | $537 |
| Alexion Pharmaceuticals | Travel · 2025-09-01 | None | $9,094 |
| Alexion Pharmaceuticals | Travel · 2025-06-25 | None | $28 |
| Alexion Pharmaceuticals | Consulting · 2025-06-25 | None | $14,625 |
| Alexion Pharmaceuticals | Travel · 2025-06-25 | None | $42 |
| Mesoblast | Meals · 2025-05-06 | Ryoncil | $112 |
| Jazz Pharmaceuticals | Meals · 2025-05-05 | Defitelio | $87 |
| Alexion Pharmaceuticals | Consulting · 2025-03-27 | Ultomiris | $175 |
| Alexion Pharmaceuticals | Meals · 2025-02-14 | None | $37 |
| Medexus Pharma | Meals · 2025-02-14 | Grafapex | $123 |
| Sobi | Meals · 2025-02-13 | Gamifant | $21 |
| Sobi | Meals · 2025-02-13 | Gamifant | $131 |
| Sobi | Meals · 2025-02-13 | Gamifant | $23 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,840
| Medexus Pharma | None | $2,040 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $780 | 1 payment
|
| ADMA BioManufacturing | None | $20 | 1 payment
|
2023: $17,404
| Alexion Pharmaceuticals | None | $16,809 | 12 payments
|
| Chiesi USA | Revcovi | $595 | 1 payment
|
2022: $17,353
| Amgen | None | $16,277 | 4 payments
|
| Chiesi USA | None | $760 | 1 payment
|
| Apellis Pharmaceuticals | Empaveli | $250 | 1 payment
|
| Jazz Pharmaceuticals | Defitelio | $67 | 1 payment
|
2021: $28,315
| Amgen | None | $15,200 | 4 payments
|
| Alexion Pharmaceuticals | Soliris | $5,100 | 5 payments
|
| Jazz Pharmaceuticals | Defitelio | $2,915 | 1 payment
|
| Chiesi USA | Ferriprox | $2,700 | 1 payment
|
| Omeros | None | $2,400 | 1 payment
|
2020: $6,324
| Omeros | Narsoplimab | $3,850 | 2 payments
|
| Amgen | None | $2,200 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $150 | 1 payment
|
| Novartis Pharmaceuticals | Kymriah | $124 | 1 payment
|
2019: $32,884
| Alexion Pharmaceuticals | Soliris | $29,157 | 24 payments
|
| Jazz Pharmaceuticals | Defitelio | $3,506 | 1 payment
|
| Vertex Pharmaceuticals | None | $221 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme Corporation · An Open-Label Phase III Trial of Caspofungin Vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections Undergoing Allogeneic Hematopoietic Cell Transplantation · 2020 | Their institution | $30,792 |
| Merck Sharp & Dohme Corporation · An Open-Label Phase III Trial of Caspofungin Vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections Undergoing Allogeneic Hematopoietic Cell Transplantation · 2021 | Their institution | $15,396 |
| National Marrow Donor Program · Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors · 2022 | Their institution | $4,200 |
| National Marrow Donor Program · Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors · 2023 | Their institution | $1,750 |
| Leadiant Biosciences, Inc. · Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (Elpegademase-Lvlr) Treatment in Ada-Scid Subjects Requiring Enzyme Replacement Therapy · 2020 | This clinician | $875 |
Professional record
- NPI
- 1861527657
- Licence
- CA A69570California A69570: Cancelled
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A695780
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X)
- Mailing address
- 2680 Hanover St, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-22
- NPI last updated
- 2008-03-24
This is when the NPI record was last certified, not a medical board exam.